GRI – gri bio, inc. (US:NASDAQ)
Stock Stats
News
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
GRI Bio Announces Closing of $8.0 Million Public Offering
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 
GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $35.00 to $36.00. They now have a "buy" rating on the stock.
Form 8-K GRI Bio, Inc. For: Jan 15
Form 8-K GRI Bio, Inc. For: Jan 15
Form 8-K GRI Bio, Inc. For: Jan 09
Form 424B5 GRI Bio, Inc.
Form 8-K GRI Bio, Inc. For: Jan 08
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.